Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options

ECONOMIC EVALUATION OF VORICONAZOLE VERSUS CASPOFUNGIN FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN BELGIUM

(2014) D. Selleslag et al.   ACTA CLINICA BELGICA

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia

(2010) D. Al-Badriyeh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

(2009) J. Menzin et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemicCandidainfections in the UK

(2009) M. K. Sidhu et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections

(2009) Robin de Vries et al.   PHARMACOECONOMICS

Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States

(2009) Amy K. O'Sullivan et al.   VALUE IN HEALTH

Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany

(2008) O. A. Cornely et al.   CURRENT MEDICAL RESEARCH AND OPINION

The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups

(2008) Kuo B. Tong et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia

(2008) D. Al-Badriyeh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases

(2008) A. Atahan Cagatay et al.   MYCOSES